Cargando…

IgG light chain-independent secretion of heavy chain dimers: consequence for therapeutic antibody production and design

Rodent monoclonal antibodies with specificity towards important biological targets are developed for therapeutic use by a process of humanisation. This process involves the creation of molecules, which retain the specificity of the rodent antibody but contain predominantly human coding sequence. Her...

Descripción completa

Detalles Bibliográficos
Autores principales: Stoyle, Chloe L., Stephens, Paul E., Humphreys, David P., Heywood, Sam, Cain, Katharine, Bulleid, Neil J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Portland Press Ltd. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5590090/
https://www.ncbi.nlm.nih.gov/pubmed/28784690
http://dx.doi.org/10.1042/BCJ20170342
_version_ 1783262466781741056
author Stoyle, Chloe L.
Stephens, Paul E.
Humphreys, David P.
Heywood, Sam
Cain, Katharine
Bulleid, Neil J.
author_facet Stoyle, Chloe L.
Stephens, Paul E.
Humphreys, David P.
Heywood, Sam
Cain, Katharine
Bulleid, Neil J.
author_sort Stoyle, Chloe L.
collection PubMed
description Rodent monoclonal antibodies with specificity towards important biological targets are developed for therapeutic use by a process of humanisation. This process involves the creation of molecules, which retain the specificity of the rodent antibody but contain predominantly human coding sequence. Here, we show that some humanised heavy chains (HCs) can fold, form dimers and be secreted even in the absence of a light chain (LC). Quality control of recombinant antibody assembly in vivo is thought to rely upon folding of the HC C(H)1 domain. This domain acts as a switch for secretion, only folding upon interaction with the LC C(L) domain. We show that the secreted heavy-chain dimers contain folded C(H)1 domains and contribute to the heterogeneity of antibody species secreted during the expression of therapeutic antibodies. This subversion of the normal quality control process is dependent on the HC variable domain, is prevalent with engineered antibodies and can occur when only the Fab fragments are expressed. This discovery will have an impact on the efficient production of both humanised antibodies and the design of novel antibody formats.
format Online
Article
Text
id pubmed-5590090
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Portland Press Ltd.
record_format MEDLINE/PubMed
spelling pubmed-55900902017-09-22 IgG light chain-independent secretion of heavy chain dimers: consequence for therapeutic antibody production and design Stoyle, Chloe L. Stephens, Paul E. Humphreys, David P. Heywood, Sam Cain, Katharine Bulleid, Neil J. Biochem J Research Articles Rodent monoclonal antibodies with specificity towards important biological targets are developed for therapeutic use by a process of humanisation. This process involves the creation of molecules, which retain the specificity of the rodent antibody but contain predominantly human coding sequence. Here, we show that some humanised heavy chains (HCs) can fold, form dimers and be secreted even in the absence of a light chain (LC). Quality control of recombinant antibody assembly in vivo is thought to rely upon folding of the HC C(H)1 domain. This domain acts as a switch for secretion, only folding upon interaction with the LC C(L) domain. We show that the secreted heavy-chain dimers contain folded C(H)1 domains and contribute to the heterogeneity of antibody species secreted during the expression of therapeutic antibodies. This subversion of the normal quality control process is dependent on the HC variable domain, is prevalent with engineered antibodies and can occur when only the Fab fragments are expressed. This discovery will have an impact on the efficient production of both humanised antibodies and the design of novel antibody formats. Portland Press Ltd. 2017-09-15 2017-09-08 /pmc/articles/PMC5590090/ /pubmed/28784690 http://dx.doi.org/10.1042/BCJ20170342 Text en © 2017 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY) (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research Articles
Stoyle, Chloe L.
Stephens, Paul E.
Humphreys, David P.
Heywood, Sam
Cain, Katharine
Bulleid, Neil J.
IgG light chain-independent secretion of heavy chain dimers: consequence for therapeutic antibody production and design
title IgG light chain-independent secretion of heavy chain dimers: consequence for therapeutic antibody production and design
title_full IgG light chain-independent secretion of heavy chain dimers: consequence for therapeutic antibody production and design
title_fullStr IgG light chain-independent secretion of heavy chain dimers: consequence for therapeutic antibody production and design
title_full_unstemmed IgG light chain-independent secretion of heavy chain dimers: consequence for therapeutic antibody production and design
title_short IgG light chain-independent secretion of heavy chain dimers: consequence for therapeutic antibody production and design
title_sort igg light chain-independent secretion of heavy chain dimers: consequence for therapeutic antibody production and design
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5590090/
https://www.ncbi.nlm.nih.gov/pubmed/28784690
http://dx.doi.org/10.1042/BCJ20170342
work_keys_str_mv AT stoylechloel igglightchainindependentsecretionofheavychaindimersconsequencefortherapeuticantibodyproductionanddesign
AT stephenspaule igglightchainindependentsecretionofheavychaindimersconsequencefortherapeuticantibodyproductionanddesign
AT humphreysdavidp igglightchainindependentsecretionofheavychaindimersconsequencefortherapeuticantibodyproductionanddesign
AT heywoodsam igglightchainindependentsecretionofheavychaindimersconsequencefortherapeuticantibodyproductionanddesign
AT cainkatharine igglightchainindependentsecretionofheavychaindimersconsequencefortherapeuticantibodyproductionanddesign
AT bulleidneilj igglightchainindependentsecretionofheavychaindimersconsequencefortherapeuticantibodyproductionanddesign